Celltrion Healthcare in KRW 41,000… Seo Jeong-jin toward ‘Bio millionaire’
Kim Min Soo | minsu@ | 2017-07-25 09:35:11
Celltrion Healthcare to be listed company on July 28
Seo Jeong-jin, CEO of Celltrion, is expected to increase its stock assets.
Celltrion Healthcare will be public offering on the KOSDAQ on July 28 is now confirmed at the top of the public offering band.
According to the financial investment industry on July 24, Celltrion Healthcare recently confirmed the offer price to KRW 41,000 at the top of domestic and foreign institutional investors` demand forecasting and the public offering of hope (KRW 32,500 ~ 41,000 ). It is reported that 285 of 89.88% of the participating institutions of the demand forecasts the top of the offer price of KRW 41,000, and 5 places (0.37%) offered the price of over KRW 41,000.
Celltrion Healthcare, which topped the list of publicly traded securities, expects its market capitalization to reach KRW 5.6 trillion. It is the second highest market succession after KOSDAQ`s ‘Great Powers’ Celltrion (KRW 13.6 trillion).
Celltrion and Celltrion Healthcare are expected to occupy the first and second positions on the KOSDAQ market, and the share value of Chairman Seo is expected to rise sharply.
According to the Financial Supervisory Service`s electronic disclosure system, Chairman Seo holds 40,945,436 shares (44.12%) of Celltrion Healthcare shares as of the end of March. If the IPO is applied at KRW 41,000, the value of Seo`s stake is estimated at KRW 2.27 trillion.
However, considering the dilution since the listing, Chairman Seo`s stake will decline to 42.12 million shares (36.8%), meaning that the actual value of the stock will be KRW 1.69 trillion.
Besides, if Celltrion Holdings and Celltrion Skin Cure, whose chairman is the largest shareholder, add KRW 70.5 billion in the stakes in Celltrion`s stake, the value of the stock will rise to KRW 2 trillion.
Celltrion Healthcare, which trades at KOSDAQ-2 on the stock market, is expected to record a positive share price even after its listing.
Shin Jae-hun, a researcher of Ebest Investment & Securities, said, "Given the rise in sales of Remsima in Europe, the rapid penetration of Remsima in the US, and the full-fledged European sales of Truxima, Celltrion Healthcare recorded sales of approximately KRW 1.3 trillion. We also believe that the valuation is attractive given the fact that the expected P / E is expected to fall to around 26x and the company is expected to post strong earnings growth in the future. Celltrion Healthcare`s revenues are estimated to range from KRW 1 trillion to KRW 1.3 trillion this year. Assuming a KRW 1 trillion FY05F PER of 27 ~ 35x and a KRW 1.3 trillion assuming 22 ~ 27x, the investment attractiveness is high.”
By Kim Min Soo minsu@
[ copyright ⓒ The Digitaltimes ]
Seo Jeong-jin, CEO of Celltrion, is expected to increase its stock assets.
Celltrion Healthcare will be public offering on the KOSDAQ on July 28 is now confirmed at the top of the public offering band.
According to the financial investment industry on July 24, Celltrion Healthcare recently confirmed the offer price to KRW 41,000 at the top of domestic and foreign institutional investors` demand forecasting and the public offering of hope (KRW 32,500 ~ 41,000 ). It is reported that 285 of 89.88% of the participating institutions of the demand forecasts the top of the offer price of KRW 41,000, and 5 places (0.37%) offered the price of over KRW 41,000.
Celltrion Healthcare, which topped the list of publicly traded securities, expects its market capitalization to reach KRW 5.6 trillion. It is the second highest market succession after KOSDAQ`s ‘Great Powers’ Celltrion (KRW 13.6 trillion).
Celltrion and Celltrion Healthcare are expected to occupy the first and second positions on the KOSDAQ market, and the share value of Chairman Seo is expected to rise sharply.
According to the Financial Supervisory Service`s electronic disclosure system, Chairman Seo holds 40,945,436 shares (44.12%) of Celltrion Healthcare shares as of the end of March. If the IPO is applied at KRW 41,000, the value of Seo`s stake is estimated at KRW 2.27 trillion.
However, considering the dilution since the listing, Chairman Seo`s stake will decline to 42.12 million shares (36.8%), meaning that the actual value of the stock will be KRW 1.69 trillion.
Besides, if Celltrion Holdings and Celltrion Skin Cure, whose chairman is the largest shareholder, add KRW 70.5 billion in the stakes in Celltrion`s stake, the value of the stock will rise to KRW 2 trillion.
Celltrion Healthcare, which trades at KOSDAQ-2 on the stock market, is expected to record a positive share price even after its listing.
Shin Jae-hun, a researcher of Ebest Investment & Securities, said, "Given the rise in sales of Remsima in Europe, the rapid penetration of Remsima in the US, and the full-fledged European sales of Truxima, Celltrion Healthcare recorded sales of approximately KRW 1.3 trillion. We also believe that the valuation is attractive given the fact that the expected P / E is expected to fall to around 26x and the company is expected to post strong earnings growth in the future. Celltrion Healthcare`s revenues are estimated to range from KRW 1 trillion to KRW 1.3 trillion this year. Assuming a KRW 1 trillion FY05F PER of 27 ~ 35x and a KRW 1.3 trillion assuming 22 ~ 27x, the investment attractiveness is high.”
By Kim Min Soo minsu@